Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens

Clinical Microbiology and Infection

Volumn 5, Issue 5, 1999, Pages 282-287

  Marchese, Anna ^a   Debbia, Eugenio A ^a   Bryskier, André ^b   Schito, Gian Carlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FROPENEM; PENEM DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL;

EID: 0033012139     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00142.x     Document Type: Article

References (16)

1. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibility of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY5555) a new oral penem, compared with those of penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime and cefdinir. Antimicrob Agents Chemother 1994; 38: 2902-4.
2. Cormican MG, Jones RN. Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and β-lactamase producing bacteria. J Antimicrob Chemother 1995; 35: 535-9.
3. Fuchs PC, Barry AL, Sewell DL. Antibacterial activity of WY-49605 compared with those of six other oral agents and selection of disk content for disk diffusion susceptibility testing. Antimicrob Agents Chemother 1995; 39: 1472-9.
4. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1995; 39: 1499-504.
5. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 1997; 39: 35-43.
6. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1997, 39: 415-18.
7. Book I. Microbiology and management of sinusitis. J Otolaryngol 1997; 25: 249-56
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd edn. Approved standard M7-A3. Villanova, PA: NCCLS, 1997.
9. Debbia EA, Marchese A, Pesce A, Saverino D, Schito GC. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens. J Chemother 1992; 4: 131-44.
10. File TM, Tan JS, Plouffe JF. Community-acquired pneumonia. Postgrad Med 1996; 99: 95-107.
11. Finch RG. The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 144-51.
12. Goldstein FW, Acar JF, the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA Collaborative surveillance study. J Antimicrob Chemother 1996; 38 (suppl A): 71-84.
13. Carratalà J, Marron A, Fernandez-Sevilla A, Liñares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1996. 24: 148-52.
14. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumoniae in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
15. Paris MM, Ranilo O, McCracken G Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 39: 2171-5.
16. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331: 377-82.